1-6 of 6
Arpankumar Patel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Free
Theodoros Vassilakopoulos, Javier Munoz, Huiqiang Huang, Ichiro Kawashima, Sung Yong Oh, Wojciech Jurczak, Juan Miguel Bergua Burgues, Ou Bai, Alejandro Berkovits, Keshu Zhou, Marc Hoffmann, Jason Westin, Maria Bouzani, Michal Kwiatek, Tai-Chung Huang, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Serena Perna, Grzegorz Nowakowski
Journal: Blood
Blood (2025) 146 (Supplement 1): 3704.
https://doi.org/10.1182/blood-2025-3704
Published: 2025
Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Free
Grzegorz Nowakowski, Marc Hoffmann, Javier Munoz, Jason Westin, Alejandro Martin Garcia-Sancho, Michal Kwiatek, Wojciech Jurczak, Maria Bouzani, Muhamad Alhaj Moustafa, Akshay Sudhindra, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Serena Perna, Theodoros Vassilakopoulos
Journal: Blood
Blood (2025) 146 (Supplement 1): 476.
https://doi.org/10.1182/blood-2025-476
Published: 2025
Journal Articles

Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma

Free
Marc Hoffmann, Theodoros Vassilakopoulos, Javier Munoz, Jason R. Westin, Maria Bouzani, Wojciech Jurczak, Michał Kwiatek, Alejandro Berkovits, Tai-Chung Huang, Akshay Sudhindra, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Grzegorz S. Nowakowski
Journal: Blood
Blood (2024) 144 (Supplement 1): 1742.2.
https://doi.org/10.1182/blood-2024-203185
Published: 2024
Journal Articles

Pharmacodynamic Biomarkers and CtDNA Support the Mechanism of Action and Clinical Efficacy of Golcadomide (CC-99282) Combined with R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Free
Mark Kaplan, Tara Basavanhally, Yumi Nakayama, Charalampos Kyriakopoulos, Arnaud Amzallag, Argyrios Gkasiamis, Arpankumar Patel, Akshay Sudhindra, Grzegorz S. Nowakowski, Jason Westin, Anita K. Gandhi
Journal: Blood
Blood (2023) 142 (Supplement 1): 1631.
https://doi.org/10.1182/blood-2023-180231
Published: 2023
Journal Articles

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Free
Marc S. Hoffmann, Javier L. Munoz, Jason Westin, Theodoros Vassilakopoulos, Alejandro Martin Garcia-Sancho, Antonio Rueda Dominguez, Wojciech Jurczak, Su-Peng Yeh, Maria Bouzani, Argyrios Gkasiamis, Mark Kaplan, Arpankumar Patel, Floriane Boucaud, Ju Li, Grzegorz S. Nowakowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4459.
https://doi.org/10.1182/blood-2023-174242
Published: 2023
Journal Articles

Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Free
Jason Westin, Alejandro Martín García-Sancho, Marc Hoffmann, Theodoros P. Vassilakopoulos, Su-Peng Yeh, Argyrios Gkasiamis, Poliana Patah, Arpankumar Patel, Ju Li, Grzegorz S. Nowakowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 9475–9477.
https://doi.org/10.1182/blood-2022-162774
Published: 2022